Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Biotechnology is a rapidly evolving field that has the potential to transform the way we
diagnose and treat diseases and is changing the landscape of healthcare. Great endeavors …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

We sought to present the epidemiology of idiopathic pulmonary fibrosis (IPF) in adults 18–64
years old in the USA. From adults aged 18–64 years in a large administrative claims data in …

600 patients aged≥ 18 years will be randomised in a 1: 1 ratio to nintedanib or placebo.
Patients with diagnosis of IPF will be excluded. The study population will be enriched with …

Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

The goal of this review is to summarise the clinical features, management, and prognosis of
acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). AE-IPF has previously been …

Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …